Navigation Links
Study challenges myth that sex late in pregnancy hastens birth

A new study debunks the widely held belief that engaging in sexual intercourse during the final weeks of pregnancy can hasten labor and delivery.

In fact, just the opposite was true in 93 women studied at Ohio State University Medical Center. Women who were sexually active in the final three weeks of their pregnancies carried their babies an average of 39.9 weeks, compared to average delivery at 39.3 weeks among women who abstained from sexual activity at term.

"Patients may continue to hear the 'old wives' tale' that intercourse will hasten labor, but according to this data, they should not hear it from the medical community," concludes Dr. Jonathan Schaffir, an obstetrician at OSU Medical Center and author of the study published in the June issue of the journal Obstetrics & Gynecology.

Schaffir also said the data don't support a recommendation to engage in sexual activity, either.

Of the 93 women enrolled, 47, or 50.5 percent, reported they had sex during the final weeks of their pregnancies ?more than any other similar study has indicated.

The participating women were those with low-risk single pregnancies enrolled at their doctor's office visit after the 37th week of pregnancy. At this and subsequent routine visits, patients were asked whether they had engaged in sexual intercourse during the preceding week and if so, how many times. Cervical examinations also were performed at each visit to gauge whether the sexual activity had a "ripening" effect on the cervix.

Schaffir found no correlation between the frequency of sexual intercourse and the score assigned to measure the cervix. That lack of change in the cervix among sexually active women, combined with the lack of difference in delivery dates among the two groups, suggests that sexual intercourse has no effect on inducing labor, Schaffir said.

He acknowledged that women who are more comfortable late in pregnancy may be more likely to engage in sexual
'"/>

Source:Ohio State University Medical Center


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
(Date:11/8/2009)...E, Ind. - Researchers at Purdue University have di...e fibers in spinal cord injuries using nano-sphere...ter an accident. , The synthetic "copolymer mice...s in diameter, or roughly 100 times smaller than t...ave been studying how to deliver drugs for cancer ...
(Date:11/6/2009)...stration is now open for the Society of Interventi...logy (IO) Therapies" Webinar, which will provide t...r treatment of liver tumors, kidney tumor ablation...zation of physicians, scientists and allied health...h through pioneering advances in image-guided ther...
(Date:11/6/2009).... 6 Auburn Hills, MI-based Law Enf...nstalling its locker system and patent-pending Bio.... Department of Health and Human Services, Nationa.... The locker system will support the NIH,s entire...ur nation,s medical research agency. The project ...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 1New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 2New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 4New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 5New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 6New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 7New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 8New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 9New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 10New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 11New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 12New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 13New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 14New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 15New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 16New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 17New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 18New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 19New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 20New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 21New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 22Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
...which trauma and burn patients are most likely to ...wide range of experimental clinical settings ?an i...outinely used in emergency rooms and intensive car...in the Proceedings of the National Academy of Scie...ng the University of Florida, describe how they we...
...iego (UCSD) have found that Lafora disease, an inh...he age of 30, can be caused by mutations in a gene...aforin. These findings are reported in the current...ciences (PNAS). , Lafora disease is characterized ..., followed by an initial seizure in the second dec...
...cancers from Nigeria, Senegal and North America ha...kely to be diagnosed with a more virulent form of ...searchers from the University of Chicago, working ...geria and the University of North Carolina, found ...ferent pattern of gene expression. Tumors from Afr...
Other Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
(Date:11/6/2009)..., SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCal... Completed transfer of Qutenza(TM) E.U. Marketing ...e significant progress in commercial readiness act...les; Senior Director, Marketing; and Director, Com...to board as director and Audit Committee chairman ...
(Date:11/6/2009)..., CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncol...tics" or the "Company") today announced updated re...N(R) in patients with sarcomas metastatic to the l...nnective Tissue Oncology Society Meeting held in M... poster presentation, entitled "A Phase II Study o...
(Date:11/6/2009)... The agenda for Arrowhead&r...ference, which is set to take place on February 22...this three day conference we will highlight key is...peakers to share their experiences. , ...009 -- The agenda for Arrowhead’s 2010 Pers...
(Date:11/5/2009)..., GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCal...d its financial results for the third quarter ende...f $3.6 million ($0.04 per share) for the three mon...s of $6.8 million ($0.08 per share) in the compara...tember 30, 2009, GenVec,s net loss was $14.1 milli...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...he Maryland Stem Cell Research,Commission (Commiss... for,new post-doctoral fellowship grants under RFA...applications from pre-doctoral students and post-,...translational research on,all types of human stem ... fellowships will be funded with each,fellowship b...
...Raptor,Pharmaceuticals Corp. ("Raptor" or the "Com... that its clinical development division, Bennu,Pha...al product candidate,EC Cysteamine. Bennu received... developed by clinical scientists at the Universit... way of its acquisition by,merger of Encode Pharma...
... 17 , - New Deal Provides a Further Opportunity f... Oxford Genome Sciences (UK) Ltd "OGeS" announces...oration with Amgen to discover, develop and,commer...ment of cancer.,This new collaboration will enable...human therapeutic antibodies (mAbs) in cancer base...
Other Biology Technology:Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
Rabbit Anti-Chicken IgY, IgG F(ab')2 fragment Antibody, Biotin Conjugated from Biomeda Corporation
Anti-Chloride Channel, CLC-2 Polyclonal Antibody, Unconjugated from CHEMICON
... 2, Monoclonal Antibody, Unconjugated Applicati...ICC: Use at an assay dependent dilution. WB: Use a...ion is determined using a whole extract of rat bra... in other applications. Optimal dilutions/concent...
Anti-TWIK-2 (Kcnk6, TOSS) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: